Gut Microbiota and Autoimmune Diseases: A Charming Real World Together with Probiotics.


Journal

Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157

Informations de publication

Date de publication:
2022
Historique:
received: 02 03 2021
revised: 28 07 2021
accepted: 18 08 2021
pubmed: 24 9 2021
medline: 24 5 2022
entrez: 23 9 2021
Statut: ppublish

Résumé

The role of gut microbiota in human disease is fascinating for hundreds of researchers worldwide. Many works have highlighted that gut microbiota modulates the immune system and that its disruption can trigger autoimmune and inflammatory immune-mediated diseases. Probiotics are able to positively modify microbiota composition. The aim of this review is to report the most important findings regarding the effects of probiotics administration in the most common autoimmune disease and inflammatory immune-mediated diseases. Literature research was performed in PubMed, Google Scholar, and Medline, as well as in specific journal websites using the keywords: "autoimmunity", "microbiota", and "probiotics". The article selection has been made independently by three authors, and controversies have been solved by a fourth researcher. Only English-language articles were included and preference was given to clinical trials, meta-analysis, and case series. After the review process, 68 articles have been considered. Relying on this evidence, many studies have investigated the potential of probiotics in restoring gut eubiosis, thus affecting pathogenesis, clinical manifestations, and course of these pathologies. Even in the light of few and sometimes contradictory studies, physicians should start to consider these preliminary findings when approaching patients suffering from autoimmune disease. After an accurate case-by-case evaluation of potential candidates, probiotics might be introduced besides the standard therapeutic plan as supportive measures.

Sections du résumé

BACKGROUND BACKGROUND
The role of gut microbiota in human disease is fascinating for hundreds of researchers worldwide. Many works have highlighted that gut microbiota modulates the immune system and that its disruption can trigger autoimmune and inflammatory immune-mediated diseases. Probiotics are able to positively modify microbiota composition.
OBJECTIVE OBJECTIVE
The aim of this review is to report the most important findings regarding the effects of probiotics administration in the most common autoimmune disease and inflammatory immune-mediated diseases.
METHODS METHODS
Literature research was performed in PubMed, Google Scholar, and Medline, as well as in specific journal websites using the keywords: "autoimmunity", "microbiota", and "probiotics". The article selection has been made independently by three authors, and controversies have been solved by a fourth researcher. Only English-language articles were included and preference was given to clinical trials, meta-analysis, and case series. After the review process, 68 articles have been considered.
RESULTS RESULTS
Relying on this evidence, many studies have investigated the potential of probiotics in restoring gut eubiosis, thus affecting pathogenesis, clinical manifestations, and course of these pathologies. Even in the light of few and sometimes contradictory studies, physicians should start to consider these preliminary findings when approaching patients suffering from autoimmune disease. After an accurate case-by-case evaluation of potential candidates, probiotics might be introduced besides the standard therapeutic plan as supportive measures.

Identifiants

pubmed: 34551690
pii: CMC-EPUB-118132
doi: 10.2174/0929867328666210922161913
doi:

Types de publication

Journal Article Meta-Analysis Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3147-3159

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Andrea Piccioni (A)

Emergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Sara Cicchinelli (S)

Emergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Federico Valletta (F)

Emergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Giulio De Luca (G)

Emergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Yaroslava Longhitano (Y)

Department of Internal Medicine, University of Genoa - Dietetics and Clinical Nutrition Unit, IRCCS Polyclinic Hospital San Martino, 16132 Genoa, Italy.

Marcello Candelli (M)

Emergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Veronica Ojetti (V)

Emergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Francesco Sardeo (F)

Emergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Simone Navarra (S)

Emergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Marcello Covino (M)

Emergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Francesco Franceschi (F)

Emergency Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH